Neurodegenerative diseases are among the top causes of mortality and the aversion of DALYs (Disability-Adjusted Life Years) worldwide. Many attempts have been made to develop therapeutics to alleviate disease symptoms without much success. The preclinical models utilized in therapeutic testing are often inaccurate and cannot precisely translate into clinical studies. The introduction of neural organoids, a three-dimensional model grown from human-originated stem cells, was able to revolutionize the field of neurological drug development. Using induced pluripotent stem cell (iPSC), scientists are able to restore adult cells pluripotency and cultivate them into region specific brain organoids using a combination of growth factors, agonists, and inhibitors. These models have proven valuable in drug screen for myriad neurodegenerative disorders. To model such diseases, iPSCs are generated from patients with the respective diseases, and then cultivated in an environment that mimics the disease environment. For example, for Parkinsons disease, Wnt pathway inhibitors and the Sonic hedgehog agonist are used to induce midbrain neural progenitor cells from patients with risk factors. Despite neural organoids wide usage in screening for neurodegenerative disorders and drug testing, neural organoids present several limitations in their function, including a lack of complexity equivalent to that of the brain. This paper will discuss neural organoid technology and provide basic insight to its usage in drug screening and the field of neuroscience.